| Document |
Document Title |
|
WO/2024/123872A1 |
The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy—induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.
|
|
WO/2024/123048A1 |
The present invention relates to a genetic construct for encoding a fusion protein having the ability to bind to a strep-tag binding material in a strain targeted by tumor cells, and a recombinant expression vector, a recombinant strain ...
|
|
WO/2024/121324A1 |
The present invention relates to a thermostable polypeptide having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleot...
|
|
WO/2024/123884A1 |
In some aspects, the present disclosure provides a method comprising: (a) incubating a composition comprising a plurality of different proteins with one or more surfaces to form a protein corona on the one or more surfaces; (b) selective...
|
|
WO/2024/124136A1 |
Disclosed herein are methods of generating an animal model of Von Willebrand Disease. The methods include administering to an animal a dual antibody treatment regimen including a Von Willebrand Factor antibody specific for Von Willebrand...
|
|
WO/2024/120528A1 |
Provided herein are helicase, Rep proteins comprising the helicase, and systems and methods using the Rep proteins for producing RNA-packaged AAV particles.
|
|
WO/2024/123814A1 |
The disclosure relates to microorganisms of the genus Paenibacillus, for the improvement of phenotypes of plants, for example nitrogen availability for non-leguminous plants. Included are novel strains of the microorganisms, microbial co...
|
|
WO/2024/124032A1 |
Genetically modified HIV-1 variants capable of infecting owl monkeys that includes one or more novel point mutations coupled with the replacement of the viral infectivity factor (Vif) gene.
|
|
WO/2024/121029A1 |
The present invention relates in a first aspect to a polynucleotide comprising an endolysin-encoding ribonucleic acid or an autolysin-encoding ribonucleic acid for use as a drug or to a polynucleotide comprising an endolysin-encoding rib...
|
|
WO/2024/120148A1 |
Provided is a class II diterpene cyclase derived from Isodon rubescens, which possesses a sequence of any one among SEQ ID NO: 1, 3, 5, and 7 or a sequence at least 70% identical thereto and retaining the activity of a diterpene cyclase.
|
|
WO/2024/124111A1 |
The present disclosure is directed to human receptor protein decoy constructs, also referred to as modified pathogen-binding proteins, that can bind to a variety of viruses and function as an alternative to traditional antibodies.
|
|
WO/2024/119285A1 |
Provided herein are methods for preparation of fibrinogen by purifying fibrinogen from a plasma fraction being depleted of prothrombin. The plasma fraction depleted of prothrombin is obtained, for example, by adding an anticoagulant to a...
|
|
WO/2024/123461A1 |
Provided herein are compositions and methods for treating retinal degeneration, such as an inherited retinal degeneration. In some examples, the compositions include a pigment epithelium-derived factor (PEDF) protein or a peptide thereof...
|
|
WO/2024/123730A1 |
The present disclosure provides for a vaccine comprising an Acinetobacter adhesin protein or fragment thereof and a pharmaceutically acceptable carrier or adjuvant. The vaccine may be used for treating or preventing a urinary tract infec...
|
|
WO/2024/124212A1 |
Provides are methods, devices, and systems for detection of protease and enzyme-associated disease and biomarkers for the same in clinical and biological samples.
|
|
WO/2024/120538A1 |
Provided are a VAR2CSA recombinant protein, a preparation method therefor, and use thereof. The provided VAR2CSA recombinant protein and the preparation method therefor feature good stability and high yield, as well as good efficiency an...
|
|
WO/2024/044691A9 |
Disclosed herein are compositions comprising chemically modified adeno-associated viruses (AAV) engineered by chemical modification of capsid proteins, whether wildtype or engineered, and methods of using such modified AAVs for therapeut...
|
|
WO/2024/124242A2 |
Disclosed herein is a genetically engineered natural killer (NK) cell and methods and uses thereof.
|
|
WO/2024/119598A1 |
Provided are an adeno-associated virus mutant having resting or activated T cell targeting and use thereof. The amino acid sequence of a heterologous peptide having T cell targeting is a sequence set forth in any one of SEQ ID No. 1-5, a...
|
|
WO/2024/120506A1 |
The present invention belongs to the field of biopharmaceutics, provides a modified cell and use thereof, and particularly relates to a method for culturing a cell. The method comprises reducing the expression and/or weakening the activi...
|
|
WO/2024/119431A1 |
The present disclosure describes the identification of LilrB3 as a receptor for APOE4. The present disclosure also provides variants of LilrB3, variants of APOE4, screening methods using LilrB3 (or variants thereof) and APOE4 (or variant...
|
|
WO/2024/121128A1 |
The invention relates to the field of immunoassay, in particular, of immunomolecular assay. The invention provides an internal control for use in immunomolecular assay such as dual-recognition immunoassay or proximity ligation assay. Suc...
|
|
WO/2024/123975A2 |
This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize a FOXM1 epitope, such as TCRs that r...
|
|
WO/2024/121798A1 |
The present disclosure relates generally to envelope-binding proteins and their use in methods of producing and/or purifying an enveloped virus from cell culture.
|
|
WO/2024/123622A1 |
Target-binding polypeptide are disclosed that include an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NO:1-12, nucleic acids encoding such polypeptides, and methods fo...
|
|
WO/2024/121254A1 |
The present invention relates to polypeptides capable of specifically recognizing and binding to the neutral amino acid transporter ASCT1/SLC1A4, while not binding to the related neutral amino acid transporter ASCT2/SLC1A5. The present i...
|
|
WO/2024/120397A1 |
A programmed design method for a topological protein. The method comprises the following steps: i) splitting the original structure of a target protein and, according to a target topological structure, designing possible reconnection mod...
|
|
WO/2024/121150A1 |
The present invention relates to genetically altered plants, parts thereof and plant cells that comprise one or more mutations in one or more NLR proteins, such as the helper NLR proteins, NRC2 and/or NRC3, as well as methods of providin...
|
|
WO/2024/119750A1 |
Provided is a nucleic acid encoding human HGF and use thereof. The nucleic acid comprises one or more open reading frames ORF, and the nucleic acid sequence of the ORF has at least 80%sequence homology with the nucleic acid sequence sele...
|
|
WO/2024/119233A1 |
Provided are methods for the prognosis and/or diagnosis of cancer, particularly ovarian cancer. Also provided are methods for the treatment of ovarian cancer as well as Chimeric Antigen Receptors (CARs) and CAR-expressing cells for the t...
|
|
WO/2024/121210A1 |
The invention relates to a novel epitope of PTPRZ1 which presents good immunogenicity and is useful for immunotherapy of cancer.
|
|
WO/2024/121751A1 |
The present invention relates to novel peptides extracted from the mucus of Halobatrachus didactylus, methods of obtaining such peptides, the extract derived from the mucus containing these peptides, and various applications of these pep...
|
|
WO/2024/068768A9 |
The present application relates to Leishmania host cells, methods of engineering Leishmania host cells, methods of culturing Leishmania host cells, methods of making a polypeptide of interest using a Leishmania host cell, and polypeptide...
|
|
WO/2024/120511A1 |
The present disclosure provides a polynucleotide and recombinant AAV encoding human FVIII. The present disclosure also provides a method of treating hemophilia A comprising administering the recombinant AAV to a subject in need thereof.
|
|
WO/2024/121317A1 |
The invention relates to a process for producing a lactoferrin-containing product by cation exchange using milk with a lactoferrin concentration of at least 4.0 per gram protein. The invention also relates to a lactoferrin-containing pro...
|
|
WO/2024/123193A1 |
The invention relates to a method of producing agglomerated hydrolysed collagen by means of non-enzymatic proteolysis, using flesh from the intestine or dermis of cattle as a raw material, which is taken as solid waste from the leather t...
|
|
WO/2024/120537A1 |
The present disclosure belongs to the field of biopharmaceutics and relates to recombinant VAR2CSA that can detect a specific typing of oncofetal chondroitin sulfate (ofCS) and oncofetal chondroitin sulfate modified proteoglycan (ofCSPG)...
|
|
WO/2024/119819A1 |
The present invention relates to a polypeptide tag and the use thereof, and specifically provides a polypeptide tag which has: (1) a sequence as shown in any one of SEQ ID NOs: 1-11, or, (2) a sequence having at least 80%, at least 90%, ...
|
|
WO/2024/123562A2 |
Disclosed herein are new peptide inhibitors of beta-lactamase that can improve the efficacy of currently available antibiotics. Methods of using the peptide inhibitors for treating bacterial infections are also disclosed.
|
|
WO/2024/120199A1 |
Provided is a new protein with four chains. The new protein is a bispecific or multispecific protein. Further provided are an isolated polynucleotide encoding the heavy chain 1, 2, the light chain 1 or 2 of the new protein, a set of isol...
|
|
WO/2024/121409A1 |
The present disclosure provides an improved binding molecule comprising an immunoglobulin binding domain, with affinity for a peptide tag moiety. The binding molecule is for example useful as a part of a bispecific conjugate. It exhibits...
|
|
WO/2024/124169A1 |
Described are immune cells (e.g., macrophages) expressing a chimeric antigen receptor or polypeptide targeted to a tumor cell antigen (e.g., CD19 or HER2) and a secondary protein or polypeptide that includes an inhibitor of the SIRPa and...
|
|
WO/2024/123682A1 |
The present disclosure relates, in part, to methods and compositions for generating modified pluripotent cells, such as modified pluripotent cells comprising a polynucleotide encoding a chimeric antigen receptor (CAR) and genetic disrupt...
|
|
WO/2024/121521A1 |
The invention relates to new cell-penetrating peptides comprising or consisting of an amino acid sequence selected from the sequences SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8. Th...
|
|
WO/2024/122470A1 |
The purpose of the present invention is to provide a protein that has high reactivity with a plurality of members among sugar nucleotides each having an N-acetylhexosamine bound thereto and has an enzymatic activity of transferring a plu...
|
|
WO/2024/123896A2 |
Disclosed herein are sortilin binding agents, including conjugate agents comprising a sortilin binding moiety, directly or indirectly conjugated with a payload moiety, compositions comprising the same as well as methods of making and usi...
|
|
WO/2024/119724A1 |
The present invention provides a collagen peptide, comprising one or more amino acid sequences as shown in SEQ ID NO. 1 and/or SEQ ID NO. 2, or one or more amino acid sequences having 95% or more identity to the amino acid sequences as s...
|
|
WO/2024/122459A1 |
The present invention addresses the problem of achieving an early determination of a cognitive dysfunction stage of a subject. Provided is a method for determining a cognitive dysfunction stage a subject is in, the method comprising: a s...
|
|
WO/2024/123835A1 |
Described herein are engineered cytokine receptor switches that can include a signal peptide, an extracellular activator binding domain, a hinge, a transmembrane domain, and/or an intracellular signaling domain. Binding of an activator t...
|
|
WO/2024/121777A1 |
Dosing regimens and methods for administering combination therapies combining a CD47 blocking agent and an anti-BCMA / anti-CD3 bispecific antibody are provided. The dosing regimens and methods may further include additional therapeutic ...
|
